Last reviewed · How we verify
Hydrocortisone Acetate 1% Ointment
At a glance
| Generic name | Hydrocortisone Acetate 1% Ointment |
|---|---|
| Also known as | Texacort ointment, ATC code H02AB09 |
| Sponsor | Sohag University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
- Sore Throat After Open Neck Elective Surgery (PHASE4)
- A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone (PHASE2)
- StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients (NA)
- Tacrolimus Versus Hydrocortisone in Atopic Dermatitis (PHASE4)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo (PHASE1, PHASE2)
- Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrocortisone Acetate 1% Ointment CI brief — competitive landscape report
- Hydrocortisone Acetate 1% Ointment updates RSS · CI watch RSS
- Sohag University portfolio CI